113 related articles for article (PubMed ID: 2592819)
41. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
42. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
43. [Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma].
Tsukamoto T; Tanoguchi H; Nakazono M; Murai M; Tachibana M; Deguchi N; Baba S; Hata M; Jitsukawa S; Tazaki H
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3259-64. PubMed ID: 3688891
[TBL] [Abstract][Full Text] [Related]
44. [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
Dozono H; Yasuda M; Yokoyama S; Takahashi S; Ochiai K; Tsuruoka M; Morimoto O; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Nov; 39(11):1968-72. PubMed ID: 3429979
[TBL] [Abstract][Full Text] [Related]
45. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
46. [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Nakabayashi T; Nakai Y; Kurita Y; Fukuoka M; Onoshi T; Ogura T; Sakuma A; Niitani H; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):97-109. PubMed ID: 9464335
[TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
Terauchi F; Moritake T; Yamamoto Y; Ogura H
Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
[TBL] [Abstract][Full Text] [Related]
48. Synergistic protective effect of
Abdel-Wahab WM; Moussa FI; Saad NA
Drug Des Devel Ther; 2017; 11():901-908. PubMed ID: 28356716
[TBL] [Abstract][Full Text] [Related]
49. The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors.
Uozumi J; Koikawa Y; Yasumasu T; Tokuda N; Kumazawa J
Int J Urol; 1996 Sep; 3(5):343-7. PubMed ID: 8886909
[TBL] [Abstract][Full Text] [Related]
50. [Clinical trial of cisplatin in the treatment of ovarian carcinoma].
Yoshizawa H; Kanazawa K; Takeuchi S; Okamura Y; Goto S; Kajiwara T
Gan To Kagaku Ryoho; 1982 May; 9(5):822-30. PubMed ID: 6764112
[TBL] [Abstract][Full Text] [Related]
51. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
52. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
[TBL] [Abstract][Full Text] [Related]
53. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Shibuya M; Hirosawa A; Niitani H
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):950-6. PubMed ID: 2111664
[TBL] [Abstract][Full Text] [Related]
54. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
[TBL] [Abstract][Full Text] [Related]
55. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
56. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
57. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
58. [Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Tohnai I; Kawabe Y; Nakashima T; Yamagiwa M; Suzuki T; Mizuno A; Mineda H
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2567-78. PubMed ID: 1702133
[TBL] [Abstract][Full Text] [Related]
59. [Protective effect of urinastatin on ischemic renal injury in rabbits].
Kihara K; Nagata N; Takasaki M
Nihon Jinzo Gakkai Shi; 1991 Jul; 33(7):673-7. PubMed ID: 1684217
[TBL] [Abstract][Full Text] [Related]
60. [Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
Fujioka H; Tada Y; Nakano E; Matsuda M; Osafune M; Sagawa S; Takaha M; Sonoda T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1612-6. PubMed ID: 6541019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
